Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 8/20 | 0.39 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18990450 | 1.00 | AAK1 (0.45) | AAK1SUCNR1GPR88LATS1ROCK2 | |
| SCHEMBL31079975 | 1.00 | AAK1 (0.45) | AAK1SUCNR1GPR88LATS1ROCK2 | |
| SCHEMBL29357190 | 0.92 | AAK1 (0.45) | AAK1GPR88LATS1ROCK2ROCK1 | |
| SCHEMBL18990566 | 0.77 | SUCNR1 (0.47) | SUCNR1CA12CA1CA2CA9 | |
| SCHEMBL18990569 | 0.77 | SUCNR1 (0.47) | SUCNR1CA12CA1CA2CA9 | |
| SCHEMBL29357754 | 0.76 | GPR88 (0.41) | SUCNR1GPR88LATS1CA12CA1 | |
| SCHEMBL31080074 | 0.76 | SUCNR1 (0.43) | SUCNR1GPR88CA12CA1CA2 | |
| SCHEMBL17784777 | 0.76 | STK17B (0.48) | LATS1ALOX5APMALT1 | |
| SCHEMBL23640753 | 0.74 | KDM4D (0.58) | LATS1CA12CA1CA2CA9 | |
| SCHEMBL17310202 | 0.74 | DYRK1A (0.49) | LATS1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| EP-3390357-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106064-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | BMX, BTK, ABCB11 | AAK1 3204/4885SUCNR1 2417/4885GPR88 911/4885 |
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | SQLE, ABCB11, BMX | AAK1 2959/4885SUCNR1 2659/4885GPR88 747/4885 |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | ABCB11, SQLE, BMX | AAK1 2994/4885SUCNR1 2712/4885GPR88 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.